Background:  A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF). Trial Registration No: Eudract-Nr. 2016-002299-28   NCT02929329 ( Link  Trial Status: recruitment stopped Enrolling Centers:  worldwide, 8250 Patients randomized in Basel 14  Core Study Team: 
© Christian Mueller, 2012 - 2020 │  Disclaimer  │  Imprint  │  Webmaster │ Last Update: July 2020
Home News Team Studies Publications Events Cooperations Contact Beate Hartmann Ph.D Kristin Shrestha Sabrina Stefanelli Dr. Samyut Shretha Cornelia Simmen